• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Diversey to be Acquired by Solenis for $4.6 Billion

    3/8/23 6:59:00 AM ET
    $DSEY
    Specialty Chemicals
    Consumer Discretionary
    Get the next $DSEY alert in real time by email

    Diversey Public Shareholders to Receive $8.40 Per Share in Cash in "Go Private" Transaction

    Combined company will allow for expanded markets and additional sustainable solutions

    Solenis ("Solenis") and Diversey Holdings, Ltd. ("Diversey" or the "Company") (NASDAQ:DSEY) today announced they have entered into a definitive merger agreement under which Solenis will acquire Diversey in an all-cash transaction valued at an enterprise value of approximately $4.6 billion. Upon completion of the merger, Diversey will become a private company.

    Under the terms of the agreement, Diversey shareholders (other than shareholders affiliated with Bain Capital Private Equity ("Bain Capital")) will receive $8.40 per share in cash, which represents a premium of approximately 41.0% over Diversey's closing share price on March 7, 2023, the last full trading day prior to the transaction announcement, and a premium of approximately 59.0% over Diversey's 90-day volume-weighted average price (VWAP). Bain Capital will receive $7.84 per share in cash and will rollover a portion of its shares of Diversey into an affiliate of Solenis in exchange for common and preferred units of such affiliate.

    Headquartered in Wilmington, Delaware, Solenis is a leading manufacturer of specialty chemicals used in water-intensive industries, which was acquired by Platinum Equity in 2021. Diversey is a leading provider of hygiene, infection prevention and cleaning solutions based in Fort Mill, South Carolina.

    "The merger presents a unique opportunity to enhance value and create a more diversified business with increased scale, broader global reach, and superior customer service capabilities. It will enable the combined company to grow and provide a number of attractive cross-selling opportunities, including meeting increasing customer demand for water management, cleaning and hygiene solutions," said Phil Wieland, Chief Executive Officer of Diversey.

    Solenis CEO John Panichella will lead the combined company following the transition and integration.

    "This is a strategic combination of two leading global products, services, and technologies providers with proven track records of product innovation who offer truly differentiated solutions to customers," said Mr. Panichella. "In combining these two complementary businesses, we expect to usher in a new and exciting chapter in our long history of helping customers tackle core challenges such as water and energy management, partnering on sustainability issues to work towards a cleaner, safer world, and reducing environmental impacts. With continued support from Platinum Equity and now Bain Capital, we are confident that we'll maximize the opportunities ahead."

    "This is a merger of two leading businesses that is fully complementary," added Eric Foss, Non-Executive Chairman of the Board of Directors of Diversey. "We believe the transaction creates significant value realization for our shareholders."

    Transaction Details

    Solenis is a portfolio company of Platinum Equity. Bain Capital, which invested in Diversey in 2017 and subsequently took the Company public in 2021, is currently the largest shareholder of Diversey. Under the terms of the transaction, Bain Capital will contribute approximately 56% of its existing equity into Solenis at an implied value per Diversey share of $7.84 and will sell its remaining shares to Solenis for cash at the same price. After negotiations with a special committee of Diversey's Board of Directors composed entirely of independent directors (the "Special Committee"), Bain Capital agreed to accept less consideration per share than the consideration to be paid to the other holders of Diversey's shares.

    Diversey's Board of Directors formed the Special Committee to evaluate and negotiate the transaction with the assistance of independent financial and legal advisors. Following this process, the Special Committee unanimously determined that the transaction with Solenis is in the best interests of Diversey and its shareholders, and, acting upon unanimous recommendation by the Special Committee, the Diversey Board of Directors unanimously approved the merger and recommended that Diversey shareholders vote in favor of the merger. The Special Committee negotiated the terms of the merger agreement with assistance from its independent financial and legal advisors.

    In connection with the transaction, Solenis has entered into a support agreement with Bain Capital, pursuant to which Bain Capital has agreed to vote all of its Diversey shares (which represent approximately 73% of Diversey's outstanding shares) in favor of the transaction, subject to certain terms and conditions set forth therein. Solenis intends to finance the transaction with a combination of committed debt and equity financing, including the contribution by Bain Capital.

    The merger is expected to be completed in the second half of 2023, subject to the satisfaction of customary closing conditions, including approval by Diversey shareholders holding a majority of the outstanding shares of the Company and receipt of regulatory approvals. Upon closing of the transaction, Diversey's ordinary shares will no longer be listed on any public market.

    Fourth Quarter and Full Year 2022 Earnings Conference Call Update

    In light of today's announcement, Diversey will not host an earnings conference call or provide financial guidance in conjunction with its earnings release for the fourth quarter and full year 2022 financial results. Going forward, Diversey will issue earnings releases consistent with its current schedule, including financial results for the fourth quarter and full year 2022, but will suspend hosting earnings conference calls and webcasts.

    Advisors

    Evercore is serving as financial advisor to the Special Committee and Wachtell, Lipton, Rosen & Katz is serving as the Special Committee's legal counsel.

    J.P. Morgan Securities LLC and Centerview Partners LLC are serving as financial advisors to Diversey on the transaction. Kirkland & Ellis LLP is providing legal counsel to Bain Capital and Diversey.

    BofA Securities, Goldman Sachs and Piper Sandler are serving as financial advisors to Solenis on the transaction. Gibson, Dunn & Crutcher LLP is providing legal counsel and Willkie Farr & Gallagher LLP is providing debt financing counsel to Platinum Equity and Solenis. BofA Securities and Goldman Sachs are leading the debt financing for the acquisition.

    About Diversey

    Diversey's purpose is to go beyond clean to take care of what's precious through leading hygiene, infection prevention and cleaning solutions. We develop and deliver innovative, mission-critical products, services and technologies that save lives and protect our environment. Over the course of 100 years, the Diversey brand has become synonymous with product quality, service and innovation. Our fully-integrated suite of solutions combines patented chemicals, dosing and dispensing equipment, cleaning machines, services and ancillary digital analysis and serves more than 85,000 customers in over 80 countries via our vast network of approximately 9,000 employees globally.

    For additional information about Diversey, please visit www.Diversey.com or follow us on LinkedIn, Facebook, or Twitter @Diversey.

    About Solenis

    Solenis is a leading global producer of specialty chemicals focused on delivering sustainable solutions for water-intensive industries, including the pulp, packaging paper and board, tissue and towel, oil and gas, petroleum refining, chemical processing, mineral processing, biorefining, power, municipal, and pool and spa markets. The company's product portfolio includes a broad array of water treatment chemistries, process aids and functional additives, as well as state-of-the-art monitoring and control systems. These technologies are used by customers to improve operational efficiencies, enhance product quality, protect plant assets, minimize environmental impact and maintain healthy water. Headquartered in Wilmington, Delaware, the company has 49 manufacturing facilities strategically located around the globe and employs a team of over 6,500 professionals in 130 countries across six continents. Solenis is a 2022 US Best Managed Company.

    For additional information about Solenis, please visit www.Solenis.com or follow us on social media.

    About Bain Capital Private Equity

    Bain Capital Private Equity has partnered closely with management teams to provide the strategic resources that build great companies and help them thrive since its founding in 1984. Bain Capital Private Equity's global team of more than 250 investment professionals creates value for its portfolio companies through its global platform and depth of expertise in key vertical industries including healthcare, consumer/retail, financial and business services, industrials, and technology, media and telecommunications. Bain Capital Private Equity has 23 offices on four continents. The firm has made primary or add-on investments in more than 1,100 companies since its inception. For more information, visit www.baincapitalprivateequity.com.

    About Platinum Equity

    Founded in 1995 by Tom Gores, Platinum Equity is a global investment firm with approximately $36 billion of assets under management and a portfolio of approximately 50 operating companies that serve customers around the world. Platinum Equity specializes in mergers, acquisitions and operations – a trademarked strategy it calls M&A&O® – acquiring and operating companies in a broad range of business markets, including manufacturing, distribution, transportation and logistics, equipment rental, metals services, media and entertainment, technology, telecommunications and other industries. Over the past 27 years Platinum Equity has completed more than 350 acquisitions.

    Cautionary Statement Regarding Forward-Looking Statements

    This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which include all statements that do not relate solely to historical or current facts, such as statements regarding the Company's expectations, intentions or strategies regarding the future, including strategies or plans as they relate to the proposed transaction. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "aim," "potential," "continue," "ongoing," "goal," "can," "seek," "target" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements are based on management's beliefs, as well as assumptions made by, and information currently available to, the Company. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected and are subject to a number of known and unknown risks and uncertainties, including: (i) uncertainties as to the timing of the proposed transaction; (ii) the risk that the merger may not be completed in a timely manner or at all, which may adversely affect the Company's business and the price of the Company's shares; (iii) the possibility that competing offers or acquisition proposals for the Company will be made; (iv) the failure to satisfy any of the conditions to the consummation of the proposed transaction, including the adoption of the merger agreement by the Company's shareholders and the receipt of certain regulatory approvals; (v) the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement, including in certain circumstances requiring the Company to pay a termination fee; (vi) the effect of the announcement or pendency of the proposed transaction on the Company's stock price, business relationships, operating results and business generally; (vii) risks that the proposed transaction may disrupt the Company's current business plans and operations; (viii) the Company's ability to retain and hire key personnel in light of the proposed transaction; (ix) risks related to diverting management's attention from the Company's ongoing business operations; (x) unexpected costs, charges or expenses resulting from the proposed transaction; (xi) the ability of the buyer to obtain the necessary financing arrangements set forth in the commitment letters received in connection with the merger; (xii) potential litigation relating to the merger that could be instituted against parties to the Merger Agreement or other transaction agreements or their respective directors, managers or officers, including the effects of any outcomes of such litigation; (xiii) certain restrictions during the pendency of the merger that may impact the Company's ability to pursue certain business opportunities or strategic transactions; (xiv) uncertain global economic conditions which have had and could continue to have an adverse effect on our consolidated financial condition and results of operations; (xv) the continuation of the COVID-19 pandemic may cause disruptions to the Company's operations, customer demand, and its suppliers' ability to support the Company; (xvi) the risks associated with the global nature of the Company's operations; (xvii) fluctuations between non-U.S. currencies and the U.S. dollar; (xviii) political and economic instability and risk of government actions affecting the Company's business and its customers or suppliers; (xix) increases in the pricing of raw materials, availability and allocation by suppliers as well as increases in energy-related costs; (xx) the Company's ability to develop new and innovative products and the acceptance of such products by the Company's customers; (xxi) cyber risks and the failure to maintain the integrity of the Company's operational or security systems or infrastructure; (xxii) the introduction of the Organization for Economic Cooperation and Development's Base Erosion and Profit Shifting; (xxiii) the consolidation of the Company's customers; (xxiv) competition in the markets for the Company's products and services and in the geographic areas in which it operates; (xxv) instability and uncertainty in the credit and financial markets and the availability of credit that the Company and its customers need to operate the Company's business; (xxvi) new and stricter regulations applicable to our business; (xxvii) continued availability of capital and financing and rating agency actions; and (xxviii) other risks described in the Company's filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as may be updated or supplemented by any subsequent Quarterly Reports on Form 10-Q or other filings with the SEC. All such factors are difficult to predict and are beyond the Company's control. While the list of risks and uncertainties presented here is, and the discussion of risks and uncertainties to be presented in the proxy statement will be, considered representative, no such list or discussion should be considered a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, and legal liability to third parties and similar risks, any of which could have a material adverse effect on the completion of the merger and/or the Company's consolidated financial condition, results of operations, credit rating or liquidity. In light of the significant uncertainties in these forward-looking statements, the Company cannot assure you that the forward-looking statements in this communication will prove to be accurate, and you should not regard these statements as a representation or warranty by the Company, its directors, officers or employees or any other person that the Company will achieve its objectives and plans in any specified time frame, or at all.

    The forward-looking statements speak only as of the date they are made. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements.

    Important Information For Investors and Shareholders

    In connection with the proposed transaction, the Company intends to file with the Securities and Exchange Commission (the "SEC") and furnish to shareholders a proxy statement on Schedule 14A. The Company, certain of its affiliates and certain affiliates of Bain Capital intend to jointly file a transaction statement on Schedule 13E-3 (the "Schedule 13E-3") with the SEC. Promptly after filing its definitive proxy statement with the SEC, the Company will mail the definitive proxy statement, the Schedule 13E-3 and a proxy card to each shareholder of the Company entitled to vote at the meeting relating to the proposed transaction. This communication is not a substitute for the proxy statement or any other document that the Company may file with the SEC or send to its shareholders in connection with the proposed transaction. INVESTORS AND SHAREHOLDERS OF THE COMPANY ARE URGED TO READ THE PROXY STATEMENT, THE SCHEDULE 13E-3 AND OTHER RELEVANT MATERIALS WHEN THEY BECOME AVAILABLE BEFORE MAKING ANY VOTING OR INVESTMENT DECISION WITH RESPECT TO THE PROPOSED TRANSACTION BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE PROPOSED TRANSACTION, THE RISKS RELATED THERETO AND RELATED MATTERS. The materials to be filed by the Company will be made available to the Company's investors and shareholders at no expense to them and copies may be obtained free of charge on the Company's website at www.Diversey.com. In addition, all of those materials will be available at no charge on the SEC's website at www.sec.gov.

    Participants in the Solicitation

    The Company and its directors, executive officers, other members of its management and employees may be deemed to be participants in the solicitation of proxies of the Company's shareholders in connection with the proposed transaction under SEC rules. Investors and shareholders may obtain more detailed information regarding the names, affiliations and interests of the Company's executive officers and directors in the solicitation by reading the Company's proxy statement for its 2022 annual meeting of shareholders, the Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and the proxy statement and other relevant materials that will be filed with the SEC in connection with the proposed transaction when they become available. Information concerning the interests of the Company's participants in the solicitation, which may, in some cases, be different than those of the Company's shareholders generally, will be set forth in the proxy statement relating to the proposed transaction when it becomes available.

    No Offer or Solicitation

    This communication is not a proxy statement or solicitation of a proxy, consent or authorization with respect to the proposed transaction and is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005378/en/

    Get the next $DSEY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DSEY

    DatePrice TargetRatingAnalyst
    2/22/2023$6.00Underperform
    BofA Securities
    12/15/2022$5.80Market Perform
    BMO Capital Markets
    10/5/2022Buy → Neutral
    Citigroup
    6/16/2022$12.00 → $10.00Buy → Hold
    Jefferies
    5/20/2022$11.00 → $12.00Outperform
    Credit Suisse
    3/25/2022$11.00 → $9.00Outperform → Sector Perform
    RBC Capital Mkts
    3/11/2022$19.00 → $15.00Overweight
    Morgan Stanley
    3/11/2022$14.00 → $11.00Outperform
    RBC Capital
    More analyst ratings

    $DSEY
    Financials

    Live finance-specific insights

    See more
    • Diversey Reports First Quarter 2023 Results

      Reported sales +5.5% compared to prior year; +12.6% adjusted for constant currencyLoss before taxes of $44.3 million for the first quarter, representing loss before taxes margin of (6.4)% Adjusted EBITDA was $52.6 million, representing Adjusted EBITDA margin of 7.6% FORT MILL, S.C., May 04, 2023 (GLOBE NEWSWIRE) -- Diversey Holdings, Ltd. ("Diversey") (NASDAQ:DSEY) announces first quarter results. UnauditedFirst Quarter Ended March 31(millions) 2023  2022 % ChangeNet sales$696.0 $660.0 5.5%Loss before taxes (44.3) (37.2)(19.1)%% Margin(6.4)%(5.6)%(80) bpsNet loss (53.6) (39.1)(37.1)%Adjusted net income (loss)(1) 1.5  3.7 (59.5)%    Adjusted EBITDA(1) 52.6  60.3 (12.8)%% Margin(1) 7.6% 9.

      5/4/23 7:59:00 AM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • Diversey Reports Fourth Quarter and Full Year 2022 Results

      Reported sales +4.3% in the fourth quarter compared to prior year and full year 2022 reported sales +5.6%Net loss of $59.5 million for the fourth quarter and $169.3 million for full year 2022 Fourth quarter Adjusted EBITDA was $93.4 million, representing Adjusted EBITDA margin of 13.3%Full year Adjusted EBITDA was $330.1 million, representing Adjusted EBITDA margin of 11.9% FORT MILL, S.C., March 17, 2023 (GLOBE NEWSWIRE) -- Diversey Holdings, Ltd. ("Diversey") (NASDAQ:DSEY) announced fourth quarter and full year results.  Year Ended December 31(millions) 2022  2021 % ChangeNet sales$2,765.9 $2,618.9 5.6%Loss before taxes (185.5) (149.5)(24.1)%Net loss (169.3) (174.8)3.1%Adjusted net inc

      3/17/23 4:29:28 PM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • Diversey to be Acquired by Solenis for $4.6 Billion

      Diversey Public Shareholders to Receive $8.40 Per Share in Cash in "Go Private" Transaction Combined company will allow for expanded markets and additional sustainable solutions Solenis ("Solenis") and Diversey Holdings, Ltd. ("Diversey" or the "Company") (NASDAQ:DSEY) today announced they have entered into a definitive merger agreement under which Solenis will acquire Diversey in an all-cash transaction valued at an enterprise value of approximately $4.6 billion. Upon completion of the merger, Diversey will become a private company. Under the terms of the agreement, Diversey shareholders (other than shareholders affiliated with Bain Capital Private Equity ("Bain Capital")) will receive

      3/8/23 6:59:00 AM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary

    $DSEY
    Leadership Updates

    Live Leadership Updates

    See more
    • Diversey Announces Appointment of Eric Foss as Chairman of the Board

      FORT MILL, S.C., March 17, 2022 (GLOBE NEWSWIRE) -- Diversey Holdings, Ltd. (NASDAQ:DSEY), a leading provider of hygiene, infection prevention and cleaning solutions, today announced that its Board of Directors has appointed Eric Foss as Chairman of the Board effective March 17. Foss succeeds Selim Bassoul who will remain a Director. Mr. Foss has been a Director since Diversey's IPO in March 2021. "Eric is a highly successful leader, with a proven track record of driving growth, creating sustainable shareholder value, building high performance teams and creating a purpose driven legacy for global at scale companies," said Phil Wieland, Diversey's CEO. "I look forward to continuing to w

      3/17/22 8:30:00 AM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • Diversey Appoints Katherine S. Zanotti to its Board of Directors

      FORT MILL, S.C., March 01, 2022 (GLOBE NEWSWIRE) -- Diversey Holdings, Ltd. (NASDAQ:DSEY), a leading provider of hygiene, infection prevention and cleaning solutions, has appointed Katherine S. Zanotti to the company's board of directors, effective March 1, 2022. This appointment will bring the total number of directors to eleven. "We are delighted to welcome Katherine (‘Kay') to our board. Kay's long history of leadership coupled with her extensive experience in sales and marketing within the foodservice and health care sectors makes her a great addition and helps position Diversey for continued growth and success," said Phil Wieland, CEO of Diversey.     Katherine S. Zanotti served as

      3/1/22 8:30:00 AM ET
      $CUTR
      $DSEY
      $EXAS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Specialty Chemicals
      Consumer Discretionary
    • Diversey Appoints Rod Hochman, M.D. to its Board of Directors

      FORT MILL, S.C., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Diversey Holdings, Ltd. (NASDAQ:DSEY), a leading provider of hygiene, infection prevention and cleaning solutions, has appointed Rod Hochman, M.D. to the company's board of directors, effective September 1, 2021. This appointment will bring the total number of directors to ten. "We are extremely pleased to welcome Rod to our board," said Phil Wieland, CEO of Diversey. "His extensive background in the healthcare sector makes Rod a great addition and helps position Diversey for continued growth and success in that area."     Rod Hochman, M.D. has been the President and Chief Executive Officer of Providence, a not-for-profit health system s

      9/1/21 8:18:44 AM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary

    $DSEY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities resumed coverage on Diversey Holdings with a new price target

      BofA Securities resumed coverage of Diversey Holdings with a rating of Underperform and set a new price target of $6.00

      2/22/23 6:12:34 AM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • BMO Capital Markets initiated coverage on Diversey Holdings with a new price target

      BMO Capital Markets initiated coverage of Diversey Holdings with a rating of Market Perform and set a new price target of $5.80

      12/15/22 7:41:26 AM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • Diversey Holdings downgraded by Citigroup

      Citigroup downgraded Diversey Holdings from Buy to Neutral

      10/5/22 9:04:01 AM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary

    $DSEY
    SEC Filings

    See more
    • SEC Form 15-12G filed by Diversey Holdings Ltd.

      15-12G - Diversey Holdings, Ltd. (0001831617) (Filer)

      7/17/23 4:06:15 PM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13E3/A filed by Diversey Holdings Ltd. (Amendment)

      SC 13E3/A - Diversey Holdings, Ltd. (0001831617) (Subject)

      7/5/23 5:13:11 PM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form S-8 POS filed by Diversey Holdings Ltd.

      S-8 POS - Diversey Holdings, Ltd. (0001831617) (Filer)

      7/5/23 4:23:44 PM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary

    $DSEY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • New Study from Diversey shows that contact time and disinfectant formulation has a significant impact on the efficacies of disinfectant towelettes on hard, non-porous surfaces

      UTRECHT, Netherlands, June 7, 2023 /PRNewswire/ -- Diversey Holdings, Ltd. (NASDAQ:DSEY), a leading provider of hygiene, infection prevention, and cleaning solutions has demonstrated in a recent study by Purdue University that disinfectant efficacy against Candida auris (C. auris) varied significantly with both product formula and contact time having a significant impact on disinfectant efficacy. The study suggests that healthcare facilities wanting the best hygiene outcomes should use disinfectants with an EPA approved label claim against C. auris and should ensure the surface is kept wet for the contact time listed on the label.

      6/7/23 4:00:00 AM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • Diversey Reports First Quarter 2023 Results

      Reported sales +5.5% compared to prior year; +12.6% adjusted for constant currencyLoss before taxes of $44.3 million for the first quarter, representing loss before taxes margin of (6.4)% Adjusted EBITDA was $52.6 million, representing Adjusted EBITDA margin of 7.6% FORT MILL, S.C., May 04, 2023 (GLOBE NEWSWIRE) -- Diversey Holdings, Ltd. ("Diversey") (NASDAQ:DSEY) announces first quarter results. UnauditedFirst Quarter Ended March 31(millions) 2023  2022 % ChangeNet sales$696.0 $660.0 5.5%Loss before taxes (44.3) (37.2)(19.1)%% Margin(6.4)%(5.6)%(80) bpsNet loss (53.6) (39.1)(37.1)%Adjusted net income (loss)(1) 1.5  3.7 (59.5)%    Adjusted EBITDA(1) 52.6  60.3 (12.8)%% Margin(1) 7.6% 9.

      5/4/23 7:59:00 AM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • New study from Diversey shows that different choices of manual floor mopping materials provide different hygiene outcomes

      UTRECHT, Netherlands, April 24, 2023 /PRNewswire/ -- Diversey Europe Operations B.V. (NASDAQ:DSEY), a leading provider of hygiene, infection prevention, and cleaning solutions recently published a study to demonstrate the importance of floor disinfection in reducing risks associated with floor hygiene. The Authors of the study suggest that commercial facilities wanting the best hygiene outcomes and using manual floor mopping as part of their facility hygiene program should consider the use of biocidal floor products with either launderable or disposable flat mops and avoid the use of cotton string mops and neutral cleaners.

      4/24/23 4:00:00 AM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary

    $DSEY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Hanau Kenneth

      4 - Diversey Holdings, Ltd. (0001831617) (Issuer)

      7/6/23 4:16:06 PM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Bain Capital Investors Llc

      4 - Diversey Holdings, Ltd. (0001831617) (Issuer)

      7/6/23 4:12:03 PM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 4 filed by Levine Susan Bruno

      4 - Diversey Holdings, Ltd. (0001831617) (Issuer)

      7/6/23 4:09:56 PM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary

    $DSEY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Diversey Holdings Ltd.

      SC 13G - Diversey Holdings, Ltd. (0001831617) (Subject)

      2/14/22 4:17:18 PM ET
      $DSEY
      Specialty Chemicals
      Consumer Discretionary